Evidence map›Paper›PMID 36405588›Full record

SynthesisFrontiers in medicine2022

Incidence, risk factors and outcomes of acute kidney injury among COVID-19 patients: A systematic review of systematic reviews.

Tauqeer Hussain Mallhi, Yusra Habib Khan, Abdulaziz Ibrahim Alzarea, Faiz Ullah Khan, Nasser Hadal Alotaibi, Abdullah Salah Alanazi, Muhammad Hammad Butt, Ahmed D Alatawi, Muhammad Salman, Sami I Alzarea and 3 more

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Observational
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 4 countries.

Tauqeer Hussain MallhiDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Yusra Habib KhanDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Abdulaziz Ibrahim AlzareaDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Faiz Ullah KhanDepartment of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China.
Nasser Hadal AlotaibiDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Abdullah Salah AlanaziDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Muhammad Hammad ButtDepartment of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden.
Ahmed D AlatawiDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Muhammad SalmanInstitute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University, Lahore, Pakistan.
Sami I AlzareaDepartment of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Saudi Arabia.
Ziyad Saeed AlmalkiDepartment of Clinical Pharmacy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia.
Mansoor A AlghaziDepartment of Pharmaceutical Care, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Majed Ahmed AlgarniDepartment of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia.
Al Jouf University · SAKing Abdulaziz Medical City · SALahore College for Women University · PKPrince Sattam Bin Abdulaziz University · SATaif University · SAUppsala University · SEXi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 associated acute kidney injury (CAKI) has emerged as a potential intricacy during the management of patients. Navigating the rapidly growing body of scientific literature on CAKI is challenging, and ongoing critical appraisal of this complication is essential. This study aimed to summarize and critically appraise the systematic reviews (SRs) on CAKI to inform the healthcare providers about its prevalence, risk factors and outcomes. All the SRs were searched in major databases (PubMed, EMBASE, Web of Science) from inception date to December 2021. This study followed SR of SRs methodology, all the records were screened, extracted and subjected to quality assessment by assessing the methodological quality of systematic reviews (AMSTAR-2). The extracted data were qualitatively synthesized and tabulated. This review protocol was registered in PROSPERO (CRD42022299444). Of 3,833 records identified; 42 SRs were included in this overview. The quality appraisal of the studies showed that 17 SRs were of low quality, while 8 moderate and 17 were of high-quality SRs. The incidence of CAKI ranged from 4.3% to 36.4% in overall COVID-19 patients, 36%-50% in kidney transplant recipients (KTRs), and up to 53% in severe or critical illness. Old age, male gender, cardiovascular disease, chronic kidney disease, diabetes mellitus and hypertension were frequently reported risk factors of CAKI. The need of renal replacement therapy (RRT) was up to 26.4% in overall COVID-19 patients, and 39% among those having CAKI. The occurrence of acute kidney injury (AKI) was found independent predictor of death, where mortality rate among CAKI patients ranged from 50% to 93%. This overview of SRs underscores that CAKI occurs frequently among COVID-19 patients and associated with high mortality, need of RRT and adverse outcomes. However, the confidence of these results is moderate to low which warrants the need of more SRs having established methodological standards. Systematic review registration: [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=299444], identifier [CRD42022299444].

Indexed as

acute kidney injurycomplicationscoronavirusCOVID-19mortalityrisk factorsSARS-CoV-2

Identifiers

PMID36405588
PMCPMC9672072
OpenAlexW4308202658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.